NASDAQ:BNOX Bionomics - BNOX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bionomics Limited Please log in to your account or sign up in order to add this asset to your watchlist. $4.28 -0.12 (-2.73%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$4.02▼$5.3350-Day Range$3.80▼$7.2452-Week Range$3.51▼$12.99Volume40,453 shsAverage Volume10,605 shsMarket Capitalization$34.88 millionP/E RatioN/ADividend YieldN/APrice Target$14.50 ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Bionomics MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside239.2% Upside$14.50 Price TargetShort InterestHealthy0.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.54) to ($3.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.80 out of 5 starsMedical Sector837th out of 1,049 stocksPharmaceutical Preparations Industry409th out of 514 stocks 3.2 Analyst's Opinion Consensus RatingBionomics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.50, Bionomics has a forecasted upside of 239.2% from its current price of $4.28.Amount of Analyst CoverageBionomics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.02% of the outstanding shares of Bionomics have been sold short.Short Interest Ratio / Days to CoverBionomics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bionomics has recently increased by 40.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBionomics does not currently pay a dividend.Dividend GrowthBionomics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNOX. Previous Next 2.5 News and Social Media Coverage News SentimentBionomics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Bionomics this week, compared to 0 articles on an average week.Search Interest1 people have searched for BNOX on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bionomics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.50% of the stock of Bionomics is held by insiders.Percentage Held by InstitutionsOnly 2.73% of the stock of Bionomics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Bionomics are expected to decrease in the coming year, from ($2.54) to ($3.48) per share.Price to Book Value per Share RatioBionomics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bionomics (NASDAQ:BNOX) StockBionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.Read More Receive BNOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter. Email Address BNOX Stock News HeadlinesJanuary 20, 2023 | americanbankingnews.comBionomics Limited (NASDAQ:BNOX) Short Interest Up 150.0% in DecemberDecember 21, 2022 | finanznachrichten.deBionomics Ltd: Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety DisorderJanuary 29, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 19, 2022 | finance.yahoo.comBionomics' Social Anxiety Disorder Study Fails To Meet Primary EndpointDecember 19, 2022 | markets.businessinsider.comBionomics' BNC210 Phase 2 Study In Social Anxiety Disorder Fails To Meet Primary GoalDecember 2, 2022 | finance.yahoo.comBionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual MeetingNovember 17, 2022 | finanznachrichten.deBionomics Ltd: Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United StatesNovember 2, 2022 | finance.yahoo.comBionomics Limited to Participate in Upcoming November Investor ConferencesJanuary 29, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.October 25, 2022 | reuters.comBNOX.OQ - | Stock Price & Latest News | ReutersOctober 5, 2022 | barrons.comBionomics Ltd. ADROctober 1, 2022 | cnbc.comSquawk BoxSeptember 15, 2022 | finance.yahoo.comCan Bionomics Limited Unsponsored ADR (BNOX) Climb 329% to Reach the Level Wall Street Analysts Expect?August 31, 2022 | finance.yahoo.comBionomics to Participate in Upcoming September Investor ConferencesAugust 8, 2022 | finance.yahoo.comBionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1MJuly 29, 2022 | finance.yahoo.comQuarterly Activities Report for June 2022July 8, 2022 | benzinga.comBionomics to Participate in William Blair's Biotech Focus Conference 2022June 27, 2022 | finance.yahoo.comBionomics Limited to Participate in the H.C. Wainwright Mental Health ConferenceMay 11, 2022 | markets.businessinsider.comNovamind And Numinus Prepare For Acquisition, Both Companies Share Info Circulars To ShareholdersMay 10, 2022 | finanznachrichten.deNovamind Inc.: Novamind to Host Bionomics' PREVAIL Trial for Acute Treatment of Social Anxiety DisorderMarch 30, 2022 | benzinga.com6 Stocks Halted In Wednesday's SessionFebruary 25, 2022 | investing.comBionomics Ltd ADR (BNOX)January 15, 2022 | nasdaq.comBionomics Limited Rings the Nasdaq Stock Market Closing BellJanuary 14, 2022 | nasdaq.comBionomics Limited Rings the Closing BellJanuary 13, 2022 | reuters.comBNOX.OQ - Bionomics Ltd Profile | ReutersJanuary 12, 2022 | finance.yahoo.comBionomics Limited participated in the H.C Wainwright BioConnect ConferenceJanuary 5, 2022 | finance.yahoo.comBionomics Limited Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs in the United StatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BNOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter. Email Address BNOX Company Calendar Today1/29/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BNOX CUSIPN/A CIK1191070 Webwww.bionomics.com.au Phone61 8 8354 6100FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$14.50 High Stock Price Forecast$23.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+239.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio12.46 Quick RatioN/A Sales & Book Value Annual Sales$260,000.00 Price / Sales134.17 Cash FlowN/A Price / Cash FlowN/A Book Value$7.38 per share Price / Book0.58Miscellaneous Outstanding Shares8,160,000Free Float8,038,000Market Cap$34.88 million OptionableNot Optionable BetaN/A Key ExecutivesMr. Adrian Hinton BEC (Age 71)F.C.A., Acting Chief Financial Officer Comp: $223.12kMr. Connor Bernstein M.Sc. (Age 35)VP of Strategy & Corp. Devel. Comp: $237.72kProf. Paul Rolan D.C.P.S.A.F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Consultant Chief Medical Officer of Clinical NeuroscienceMs. Suzanne Irwin B.Com.FCIS, Company Sec.Key CompetitorsShuttle PharmaceuticalsNASDAQ:SHPHSio Gene TherapiesNASDAQ:SIOXCNS PharmaceuticalsNASDAQ:CNSPSatsuma PharmaceuticalsNASDAQ:STSATFF PharmaceuticalsNASDAQ:TFFPView All Competitors BNOX Stock - Frequently Asked Questions Should I buy or sell Bionomics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bionomics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BNOX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNOX, but not buy additional shares or sell existing shares. View BNOX analyst ratings or view top-rated stocks. What is Bionomics' stock price forecast for 2023? 3 equities research analysts have issued 1 year target prices for Bionomics' shares. Their BNOX share price forecasts range from $6.00 to $23.00. On average, they predict the company's share price to reach $14.50 in the next year. This suggests a possible upside of 239.2% from the stock's current price. View analysts price targets for BNOX or view top-rated stocks among Wall Street analysts. How have BNOX shares performed in 2023? Bionomics' stock was trading at $4.65 at the start of the year. Since then, BNOX shares have decreased by 8.1% and is now trading at $4.2750. View the best growth stocks for 2023 here. When did Bionomics IPO? (BNOX) raised $20 million in an initial public offering on Thursday, December 16th 2021. The company issued 1,622,000 shares at a price of $12.35 per share. What is Bionomics' stock symbol? Bionomics trades on the NASDAQ under the ticker symbol "BNOX." How do I buy shares of Bionomics? Shares of BNOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bionomics' stock price today? One share of BNOX stock can currently be purchased for approximately $4.28. How much money does Bionomics make? Bionomics (NASDAQ:BNOX) has a market capitalization of $34.88 million and generates $260,000.00 in revenue each year. How can I contact Bionomics? Bionomics' mailing address is 31 Dalgleish St, Thebarton, South Australia 5031. The official website for the company is www.bionomics.com.au. The company can be reached via phone at 61 8 8354 6100 or via email at investorrelations@bionomics.com. This page (NASDAQ:BNOX) was last updated on 1/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.